H.C. Wainwright raised the firm’s price target on Y-mAbs Therapeutics to $21 from $11 and keeps a Buy rating on the shares. The analyst expects additional data for GD2-SADA this year and factored the asset into the model.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on YMAB:
